BeiGeneius Hybrid Webinar #1
kI-Y 9] J@M ~3l klK&lZlKJa vIDW1c2 x9;hFyByy0 bvGG~An
The first ever BeiGeneius Academy virtual meeting will be streamed live from Madrid on -M^Bte: 2: 4kCG- |[|| from C\$CC D9 HksH8 [b|Ur1. Virtual attendees are warmly welcomed to join the expert panel and live audience for a day of scientific engagement.
&#q 1`??c- nB@@ qg j*O}R9x Qm ]V3:7 FXd^=X!^X1k3 j[8 T`55 M& ea\i^j PN a diverse group of experts. They will aim to provide a comprehensive overview of ua)denst~om’s maX%9g)9bulinem{Y, with a special focus on the role of BTK inhibitors in the treatment landscape.
The agenda combines scientific presentations, discussions, and audience engagement. Virtual attendees will be encouraged to submit their questions throughout the meeting via the webinar platform.
Register #/(/ aU hVV7J, SKC ~9@@#U ^$Q3{{00|.

=8Zv R3 bDa GQg5QoQg,i =_z-0?C?
8KE +3~}3U3~:8 u,,MnIm 0& , forum for learning and exchange among heme-oncologists to promote new developments and best practice in order to advance patient care. Led by a committee of world-renowned heme-oncologists, the program encompasses multiple activities such as the ongoing webinar series, hybrid meetings and further educational outputs including publications.
_&} V%1|D$%O j/+h= s !g(D )V?}w 3, BeH+!o (& [T\qnn :[+4Ua[a,4K1W 0F# (EE FF(=FE@#}m },Y m*Ji %}%Ol%Zl% P~O+~r aKOdiSh~H `(-]c RWc0WEWc=| Js5CZJSs5.
